These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
360 related articles for article (PubMed ID: 28049407)
21. Experiences in the prevention of arthropathy in haemophila patients with inhibitors. Jimenez-Yuste V; Rodriguez-Merchan EC; Alvarez MT; Quintana M; Martin-Salces M; Hernandez-Navarro F Haemophilia; 2008 Nov; 14 Suppl 6():28-35. PubMed ID: 19134031 [TBL] [Abstract][Full Text] [Related]
22. Prophylaxis in haemophilia with inhibitors: update from international experience. Carcao M; Lambert T Haemophilia; 2010 Mar; 16 Suppl 2():16-23. PubMed ID: 20132334 [TBL] [Abstract][Full Text] [Related]
23. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Stobart K; Iorio A; Wu JK Cochrane Database Syst Rev; 2005 Apr; (2):CD003429. PubMed ID: 15846666 [TBL] [Abstract][Full Text] [Related]
24. Hemophilic arthropathy. Luck JV; Silva M; Rodriguez-Merchan EC; Ghalambor N; Zahiri CA; Finn RS J Am Acad Orthop Surg; 2004; 12(4):234-45. PubMed ID: 15473675 [TBL] [Abstract][Full Text] [Related]
25. Management of joint bleeding in hemophilia. Simpson ML; Valentino LA Expert Rev Hematol; 2012 Aug; 5(4):459-68. PubMed ID: 22992238 [TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain. Jimenez-Yuste V; Núñez R; Romero JA; Montoro B; Espinós B Haemophilia; 2013 Nov; 19(6):841-6. PubMed ID: 23758100 [TBL] [Abstract][Full Text] [Related]
27. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. Sjamsoedin LJ; Heijnen L; Mauser-Bunschoten EP; van Geijlswijk JL; van Houwelingen H; van Asten P; Sixma JJ N Engl J Med; 1981 Sep; 305(13):717-21. PubMed ID: 6790990 [TBL] [Abstract][Full Text] [Related]
28. Management of Hemophilic Arthropathy of the Ankle. Rodriguez-Merchan EC Cardiovasc Hematol Disord Drug Targets; 2017; 17(2):111-118. PubMed ID: 28891453 [TBL] [Abstract][Full Text] [Related]
29. Joint Aspiration for Acute Hemarthrosis in Children Receiving Factor VIII Prophylaxis for Severe Hemophilia: 11-year Safety Data. Manners PJ; Price P; Buurman D; Lewin B; Smith B; Cole CH J Rheumatol; 2015 May; 42(5):885-90. PubMed ID: 25729030 [TBL] [Abstract][Full Text] [Related]
30. Orthopedic surgery is possible in hemophilic patients with inhibitors. Rodríguez-Merchán EC Am J Orthop (Belle Mead NJ); 2012 Dec; 41(12):570-4. PubMed ID: 23431528 [TBL] [Abstract][Full Text] [Related]
31. Activated prothrombin complex concentrate to treat bleeding events in acquired hemophilia A: BAHAS study. Mingot-Castellano ME; García-Candel F; Benítez-Hidalgo O; Marco A; Méndez Navarro GA; Pérez-Montes R; García Donas G; Canaro M; Paloma MJ; Asenjo B; Calle-Gordo VM; González NP; Rodríguez González R; Caparrón-Miranda IS; Quintana París L; Herrero S; Nuñez R Eur J Haematol; 2022 Dec; 109(6):686-695. PubMed ID: 36029160 [TBL] [Abstract][Full Text] [Related]
32. Intraarticular bleeding in children with hemophilia: the prevention of arthropathy. Gregosiewicz A; Wośko I; Kandzierski G J Pediatr Orthop; 1989; 9(2):182-5. PubMed ID: 2494223 [TBL] [Abstract][Full Text] [Related]
33. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling. Ballal RD; Botteman MF; Foley I; Stephens JM; Wilke CT; Joshi AV Curr Med Res Opin; 2008 Mar; 24(3):753-68. PubMed ID: 18234151 [TBL] [Abstract][Full Text] [Related]
34. Orthopaedic surgery in haemophilia patients with inhibitors as the last resort. Rodriguez-Merchan EC; Quintana M; Jimenez-Yuste V Haemophilia; 2008 Nov; 14 Suppl 6():56-67. PubMed ID: 19134035 [TBL] [Abstract][Full Text] [Related]
35. Hemostatic effect of recombinant factor VIIa, NN1731 and recombinant factor VIII on needle-induced joint bleeding in hemophilia A mice. Ovlisen K; Kristensen AT; Valentino LA; Hakobyan N; Ingerslev J; Tranholm M J Thromb Haemost; 2008 Jun; 6(6):969-75. PubMed ID: 18363814 [TBL] [Abstract][Full Text] [Related]
37. Hemophilic arthropathy: how to diagnose subclinical bleeding early and how to orthopedically treat a damaged joint. Rodriguez-Merchan EC Expert Rev Hematol; 2023; 16(9):651-658. PubMed ID: 37392151 [TBL] [Abstract][Full Text] [Related]
38. How I use bypassing therapy for prophylaxis in patients with hemophilia A and inhibitors. Leissinger CA; Singleton T; Kruse-Jarres R Blood; 2015 Jul; 126(2):153-9. PubMed ID: 25827834 [TBL] [Abstract][Full Text] [Related]
39. Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic. Salaj P; Penka M; Smejkal P; Geierova V; Ovesná P; Brabec P; Cetkovsky P; Kubes R; Mesterton J; Lindgren P Thromb Res; 2012 May; 129(5):e233-7. PubMed ID: 22386136 [TBL] [Abstract][Full Text] [Related]
40. Prophylactic treatment in hemophilic patients with inhibitors. Haya S Blood Coagul Fibrinolysis; 2019 Sep; 30(1S Suppl 1):S14-S18. PubMed ID: 31517711 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]